Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Crystallization (Commentary)

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term:

Results 1 - 10 of 31 > >>
EC Number Crystallization (Commentary)
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21-
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21docking studies of rhodanine-3-hippuric acid and its benzylidene derivatives
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21hanging drop vapour diffusion method, using 0.1 M HEPES pH 7.5, 20% (w/v) polyethylene glycol 4000 and 10% (v/v) 2-propanol
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21homology modeling of structure, a uniform negative electrostatic potential exists over the protein surface
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21in complex with citrate and inhibitor fidarestat, resolution of 0.82 A. After the catalytic event, a rearrangement of a bound ligand can trigger the opening of the safety-belt loop of G213-S226, initiating the release of the oxidized cofactor
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21in complex with inhibitor IDD552, crystallized at pH 5 and 8
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21in complex with inhibitor zenarestat
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21in complex with inhibitors tolrestat, 2-(carboxymethyl)-1-oxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid 3,3-dioxide and 2-[2-(carboxymethoxy)-2-oxoethyl]-1-oxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid 3,3-dioxide. Unlike tolrestat, the naphthol[1,2-d]isothiazole inhibitors leave the specificity pocket in the closed state and ligand 2-(carboxymethyl)-1-oxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid 3,3-dioxide extends the catalytic pocket by opening a novel subpocket. Inhibitor 2-[2-(carboxymethoxy)-2-oxoethyl]-1-oxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid 3,3-dioxide provokes less pronounced induced-fit adaptations of the binding cavity
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21in complex with NADP+ and inhibitor 4-[3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid, 1.43 A resolution. The inhibitor occupies the active site with its carboxylate head group located at the catalytic cavity. In complex with inhibitor {[5-(5-nitrofuran-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetic acid at 1.55 A resolution. The nitro-aromatic moiety of both inhibitors occupies the specificity pocket of the enzyme, binding to the bottom of the pocket and provoking remarkable induced-fit adaptations
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21in complex with NADPH, to 2.4 A resolution. Space group P412121 or P43212
Results 1 - 10 of 31 > >>